Zambon SpA
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Zambon SpA sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Zambon SpA: 5 sponsored US clinical trials, none currently recruiting.
Zambon SpA sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 4 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Bronchiolitis Obliterans, with 2 trials.
Upper-quartile sponsor footprint
Zambon SpA sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
NCT04039347
A Retrospective Chart Review Study of Patients With Chronic Lung Allograft Dysfunction-Bronchiolitis Obliterans Syndrome (CLAD-BOS) Post Lung Transplantation
NCT06503770
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
NCT03656926
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)
NCT03657342
Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.
NCT03460704
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 4 |
How the Zambon SpA archive is shaped
5 indexed studies, none listed as recruiting (0% open); 3 completed (60%).
Phase mix: 4 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Bronchiolitis Obliterans (2 trials), 7 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Zambon SpA: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Zambon SpA sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Zambon SpA page
5 registered trials is a research-attention snapshot, not an endorsement of Zambon SpA or any single study.
- None of Zambon SpA's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Bronchiolitis Obliterans is the condition Zambon SpA studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Bronchiolitis Obliterans trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Zambon SpA pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.